Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis
Authors:
- Ewa JanczewskaEJEwa Janczewska
- Robert FlisiakRFRobert Flisiak
- Dorota Zarebska-MichalukDorota Zarebska-Michaluk
- Dorota KozielewiczDKDorota Kozielewicz
- Hanna BerakHBHanna Berak
- Beata DobrackaBDBeata Dobracka
- Marta Librant-SuskaMLMarta Librant-Suska
- Wladyslaw LojewskiWLWladyslaw Lojewski
- Krzysztof JurczykKJKrzysztof Jurczyk
- Joanna MusialikJMJoanna Musialik
- Barbara Postawa-KlosińskaBPBarbara Postawa-Klosińska
- Jacek WroblewskiJWJacek Wroblewski
Open Access
- 1 September 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (38) , e1411
Abstract
We investigated the safety, efficacy, and impact of ribavirin and peginterferon dose reduction on complete early virologic response and sustained virologic response (SVR) to triple therapy with telaprevir in treatment-experienced patients with advanced liver fibrosis.Treatment was initiated for 211 patients who failed treatment with peginterferon and ribavirin, with bridging fibrosis (F3, n = 68) or cirrhosis (F4, n = 143), including 103 (49%) null-responders (NR), 30 (14%) partial responders (PR), and 78 (37%) relapsers (REL). Impaired liver function (ILF) platelets 60% of the total ribavirin dose (23% vs 44%, respectively) or 80% of the total ribavirin dose (33% vs 48%, respectively). A significant SVR24 decrease was noted subsequent to a total peginterferon dose reduction, both when comparing patients who received 60% of the total dose (NR: 0% vs 44%; REL: 33% vs 68%) and patients who received 80% of the total dose (NR: 17% vs 50%; REL: 46% vs 71%).Serious adverse events were observed in 31 patients (15%). Deaths occurred in 4 patients. All of the deceased subjects were cirrhotic members of the ILF (baseline serum albumin level <35 g/L and/or platelet count <100,000/mm) group.Ribavirin dose reduction did not affect efficacy in REL but did in NR. Peginterferon dose reduction decreased the SVR24 rate for all groups, particularly in prior NR. ILF increased the risk of fatal complications with a low probability to achieve SVR24. One solution might be to provide wide and early access to novel, efficient, and safe interferon-free combinations to treatment-experienced patients, particularly those with liver cirrhosis.Keywords
This publication has 31 references indexed in Scilit:
- Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access programJournal of Hepatology, 2014
- Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?Antiviral Research, 2014
- Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and CirrhosisGastroenterology, 2014
- Hepatitis C treatment: an incipient therapeutic revolutionTrends in Molecular Medicine, 2014
- Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis CGut, 2013
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890Journal of Hepatology, 2013
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrowLiver International, 2011
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2011
- Telaprevir for Retreatment of HCV InfectionNew England Journal of Medicine, 2011